On March 18th, the "2024 Drug Evaluation Report" (hereinafter referred to as the "Report") was released.

In recent years, the innovation vitality of pharmaceutical research and development in China has significantly increased. According to statistics, from 2018 to 2024, China has approved a total of 197 innovative drugs for marketing; The number of innovative drugs approved for market each year has shown a steady growth trend, rising from 11 in 2018 to 48 in 2024. The report shows that in 2024, 48 Class 1 innovative drugs and 89 overseas and domestic unlisted drugs were approved, covering nearly 20 therapeutic fields such as tumors, neurological diseases, endocrine system diseases, and anti infections.

The report systematically analyzes the acceptance, review and approval of drug registration applications. From the report, it can be seen that the number of drug registration applications in China continues to grow, new and good drugs are accelerating their market launch, and the technical guidance principle system for drug research and development is closer to the present, cutting-edge, and international standards. The National Medical Products Administration (NMPA) has adopted and implemented all 71 International Conference on Harmonisation of Registration Techniques for Medicinal Products for Human Use (ICH) guidelines, and the level of implementation and compliance is similar to that of other ICH international regulatory agencies such as Europe, America, and Japan.